Published online Mar 9, 2017. doi: 10.5497/wjp.v6.i1.1
Peer-review started: November 2, 2016
First decision: December 1, 2016
Revised: January 6, 2017
Accepted: February 8, 2017
Article in press: February 10, 2017
Published online: March 9, 2017
Core tip: Fibromyalgia (FM) is a multidimensional chronic pain condition that current therapies provide modest and limited efficacy due to the heterogeneity of the condition, contribution of peripheral and central components to the pathophysiology, and a range of co-morbidities. Drugs acting on novel and existing targets, such as melatoninergic, cannabinoid, dopamine, NMDA, angiotensin, orexin and opioid receptors, ion channels, bioamine processes and subunits have provided efficacy outcomes that improve the health status of patients with FM. An understanding of the pathophysiology of FM is providing potential targets for new medications.